Clinical trials: Metastatic Progressive Breast Cancer
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
This randomized, open-label, parallel-group study will assess the efficacy and s afety of Avastin (bevacizumab) in combination with chemotherapy versus chemother apy alone as second- and third-line therapy in patients with…
- Trial name
- NCT01250379
- Testing
- bevacizumab [Avastin], Chemotherapy
- Where
- 132 sites in Argentina, Austria and 11 more
- Volunteers
- 494 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer
Target Population: female patients with HER2-negative, ER and/or PgR positive breast cancer in progression after first-line hormonal therapy.
- Trial name
- NCT01477060
- Testing
- Lapatinib, Metformin
- Where
- 11 sites in Italy
- Volunteers
- 32 people
- Sponsor
- Fondazione Michelangelo
Lung Cancer, Non Small Cell Lung Cancer (NSCLC)
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the effect of food on the pharmacokinetics (PK) of the experimental drug, entinostat, in women with breast cancer and men and women with non-small cell lung cancer.
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
- Trial name
- ENCORE110 (NCT01594398)
- Testing
- entinostat, Erlotinib, Exemestane
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Syndax Pharmaceuticals
HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI Therapy
This trial is a combination of trastuzumab and pyrotinib in the treatment of patients with HER2-positive metastatic breast cancer who have progressed on TKI therapy. A total of 50 patients were enrolled in the study design.
- Trial name
- NCT05560308
- Testing
- Trastuzumab Emtansine for Injection, Pyrotinib Maleate Tablets
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
This phase Ib trial studies the best way of TLR8 Agonist VTX-2337 and cyclophosphamide in treating patients with a solid tumor that has spread from the primary site (place where it started) to other places in the body…
- Conditions
- Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma
- Trial name
- NCT02650635
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Pegfilgrastim
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Breast Cancer, Breast Carcinoma
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
The purpose of this study is to see whether 18F-FDHT PET/MRI scans are an effective way of identifying AR-positive breast cancer.
- Conditions
- Breast Cancer, Breast Carcinoma, Metastatic Breast Cancer, Metastatic Breast Carcinoma
- Trial name
- NCT06145399
- Testing
- 18F-FDG PET/CT, [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging, 18F-FDHT
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a…
- Trial name
- CONFIRM (NCT00099437)
- Testing
- Fulvestrant
- Where
- 106 sites in United States, Belgium and 15 more
- Volunteers
- 736 people
- Sponsor
- AstraZeneca
Breast Cancer
Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer
This study is being done to find out how safe TAS-108 is and how well TAS-108 works on recurrent or recurrent inoperable breast cancer.
- Trial name
- NCT00166543
- Testing
- TAS-108
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- SRI International
Metastatic ER+ Breast Cancer
Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy
Phase1 study of TTC 352 for treatment of metastatic ER+ breast cancer.
- Trial name
- NCT03201913
- Testing
- TTC-352
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- TTC Oncology, LLC
Breast Cancer
Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment
The purpose of this clinical trial is to determine if the investigational drug is able to reduce/shrink advanced breast cancer tumors in patients who no longer benefit from anthracyclines, taxanes and capecitabine.
- Trial name
- NCT00087958
- Testing
- XRP9881
- Where
- 15 sites in United States, Argentina and 13 more
- Volunteers
- 168 people
- Sponsor
- Sanofi
Breast Neoplasms, Neoplasm Metastasis
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
The aim of this study is to investigate the efficacy and safety of afatinib alone or in combination with vinorelbine, as treatment in patients with HER2-overexpressing metastatic breast cancer, who have progressive brain lesions…
- Trial name
- NCT01441596
- Testing
- Vinorelbine, Investigator's choice of treatment, afatinib
- Where
- 40 sites in United States, Canada and 6 more
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Breast Cancer
Capecitabine With Digoxin for Metastatic Breast Cancer
To evaluate the Growth Modulation Index (GMI) of the combination of metronomic capecitabine with oral digoxin in metastatic breast cancer
- Trial name
- NCT01887288
- Testing
- Capecitabine, Digoxin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Western Regional Medical Center
Breast Cancer
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
HS-10352 is a highly potent and selective small molecule inhibitor of phosphoinositide 3-kinase (p110α). In preclinical studies, it demonstrated strong activity against PI3K p110α in vitro and in vivo, and inhibited tumor cell…
- Trial name
- NCT04631835
- Testing
- HS-10352
- Where
- 3 sites in China
- Volunteers
- 54 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
Overcoming Endocrine Resistance in Metastatic Breast Cancer
Based on these results it can be envisioned that the majority of endocrine-responsive post-menopausal breast cancer patients will be treated with an AI as adjuvant therapy (front-line, switching or extending) and/or as first-line…
- Trial name
- OVER (NCT02394496)
- Testing
- Fulvestrant, Lapatinib, Aromatase Inhibitors
- Where
- 69 sites in Italy
- Volunteers
- 396 people
- Sponsor
- Consorzio Oncotech
Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients
In the second-line treatment setting for MBC, many agents, including antitubulin drugs (Taxanes, Vinorelbine) and antimetabolites (Capecitabine, Gemcitabine), have demonstrated activity, but no agent is clearly superior.
- Trial name
- GIM11-BERGI (NCT02175446)
- Testing
- Bevacizumab and eribulin
- Where
- 17 sites in Italy
- Volunteers
- 61 people
- Sponsor
- Consorzio Oncotech
Metastatic Progressive Castration-resistant Prostate Cancer, Metastatic Progressive Breast Cancer
Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method
The primary objective of the preliminary lead-in study is to determine whether circulating tumor cells in patients with metastatic progressive castration-resistant prostate cancer or metastatic progressive breast cancer can be…
- Trial name
- CTC-EMT (NCT02025413)
- Testing
- Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Duke University
Advanced Breast Cancer, Metastatic Breast Cancer
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg
This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.
- Trial name
- FINDER II (NCT00313170)
- Testing
- Fulvestrant
- Where
- 34 sites in Belgium, Canada and 6 more
- Volunteers
- 144 people
- Sponsor
- AstraZeneca